# 3D Systems Corp: Form 10-Q for the period ended Jun 30, 2024

- Company: [3D Systems Corp](/companies/ddd.md) (CIK 910638)
- Form: 10-Q
- Filed: 2024-08-29
- Accepted by EDGAR: Aug 29, 2024, 16:31 ET
- Period: 2024-06-30
- Accession: 0000910638-24-000041
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/910638/000091063824000041/ddd-20240630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/910638/000091063824000041/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2024-04-01 to 2024-06-30 | $113.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2024-01-01 to 2024-06-30 | $216.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2024-04-01 to 2024-06-30 | $66.2m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2024-01-01 to 2024-06-30 | $128.1m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2024-04-01 to 2024-06-30 | $47.1m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2024-01-01 to 2024-06-30 | $88.0m | us-gaap:GrossProfit |
| Research and development | 3 months, 2024-04-01 to 2024-06-30 | $22.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2024-01-01 to 2024-06-30 | $45.5m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2024-04-01 to 2024-06-30 | $51.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2024-01-01 to 2024-06-30 | $108.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2024-04-01 to 2024-06-30 | −$26.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2024-01-01 to 2024-06-30 | −$66.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2024-04-01 to 2024-06-30 | $476.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2024-01-01 to 2024-06-30 | $1.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-04-01 to 2024-06-30 | −$27.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2024-01-01 to 2024-06-30 | −$43.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2024-04-01 to 2024-06-30 | −$0.21 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2024-01-01 to 2024-06-30 | −$0.33 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2024-04-01 to 2024-06-30 | −$0.21 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2024-01-01 to 2024-06-30 | −$0.33 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2024-04-01 to 2024-06-30 | 131,802,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2024-01-01 to 2024-06-30 | 131,311,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2024-01-01 to 2024-06-30 | −$36.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2024-01-01 to 2024-06-30 | $7.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2024-06-30 | $192.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-06-30 | $473.7m | us-gaap:AssetsCurrent |
| Total assets | at 2024-06-30 | $821.5m | us-gaap:Assets |
| Current liabilities | at 2024-06-30 | $137.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-06-30 | $437.7m | us-gaap:Liabilities |
| Long-term debt | at 2024-06-30 | $211.4m | us-gaap:LongTermDebtNoncurrent |

## Management's discussion and analysis

As filed, 102,793 characters.

The following discussion and analysis should be read together with our unaudited condensed consolidated financial statements and notes thereto included in Item 1 of this Quarterly Report on Form 10-Q (the “Financial Statements”). Certain statements contained in this discussion may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that may affect our future performance that are discussed in greater detail under the headings “Forward Looking Statements” below; in Part II, Item 1A, "Risk Factors" of this Quarterly Report on Form 10-Q; and in Part I, Item 1A, "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2023 (“2023 Form 10-K”).

### Business Overview

3D Systems Corporation (“3D Systems” or the “Company” or “we,” "our" or “us”) markets our products and services through subsidiaries in North America and South America (collectively referred to as “Americas”), Europe and the Middle East (collectively referred to as “EMEA”) and Asia Pacific and Oceania (collectively referred to as “APAC”). We provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. Our solutions support advanced applications in two key industry verticals: Healthcare Solutions and Industrial Solutions. We have over 35 years of experience and expertise, which have proven vital to our development of an ecosystem and end-to-end digital workflow solutions that enable customers to optimize product designs, transform workflows, bring innovative products to market and drive new business models.

The Company has two reportable segments: Healthcare Solutions and Industrial Solutions. Our reportable segments are based upon the industry verticals that they serve. For Healthcare Solutions, those industry verticals include dental, medical devices, personalized health services and regenerative medicine. For Industrial Solutions, those industry verticals include aerospace, defense, transportation and general manufacturing. We architect solutions specific to customers’ needs through a combination of materials, hardware platforms, software, professional services and advanced manufacturing – creating a path to integrating additive manufacturing into traditional production environments. As a result, manufacturers achieve design freedom, increase agility, scale production and improve their overall total cost of operation. Our technologies and process knowledge enable over a million production parts to be made through additive manufacturing each day.

### Recent Developments and Updates Regarding Strategic Initiatives

### Ongoing Fiscal Year 2023 Restructuring Plan

#### Restructuring Plan Objectives and Status of Execution

In 2023, the Company commenced a multi-faceted restructuring plan (the “2023 Restructuring Plan”) to improve operating efficiencies throughout the organization and drive long-term value creation. The key initiatives of the plan, some of which are ongoing, were announced in 2023 and included:

- improving manufacturing efficiencies related to the Company’s European metal printer operations by (1) in-sourcing certain metal printer platforms into the Company’s Riom, France manufacturing facility and (2) co-locating the engineering and manufacturing of in-sourced metal printer products in order to improve cycle time from development to production;
- reducing headcount throughout all functions and areas of the organization;
- rationalizing the Company's geographic footprint through the exit of leased facilities; and
- reducing certain third-party costs.

As of June 30, 2024, the Company has substantially completed its in-sourcing activities. Actions taken to reduce headcount commenced during the year ended December 31, 2023, continued throughout the three and six months ended June 30, 2024, and are expected to be substantially completed during the quarter ended September 30, 2024. Beginning during our fourth quarter ended December 31, 2023, and continuing throughout the six months ended June 30, 2024, the Company (1) has been identifying and evaluating its opportunities to exit leased facilities, (2) has been both developing and has commenced execution against its relocation plans, and (3) is actively marketing facilities that have been successfully exited for sublease. The decision-making, planning and execution related to our planned facility exits will continue throughout 2024 and into 2025. In addition, the Company has ongoing actions related to the reduction of third-party costs.

#### 2023 Restructuring Plan Costs, Cash Settlements and Recognized Liabilities

Since inception of the 2023 Restructuring Plan, we have incurred $7.9 million related to headcount reductions. These charges relate to employee severance and termination benefit costs that are generally recognized when probable and estimable because they are typically being determined consistent with the Company’s past practices or statutory law.

The severance, termination benefits and other employee costs that have been incurred during the six months ended June 30, 2024 and 2023 are reflected in our consolidated statement of operations as follows:

*(in thousands)*

|  | June 30, 2024 | June 30, 2023 |
| --- | ---: | ---: |
| Balance at beginning of period | $3,933 | $— |
| Costs incurred during the period | (351) | 3,018 |
| Amounts settled with cash | 2,304 | 1,962 |
| Balance at the end of period | $1,278 | $1,056 |

As of June 30, 2024, we have incurred $0.5 million in lease termination costs and, during 2023, we recorded $0.6 million in incremental impairment charges related to certain fixed assets that have been retired in connection with the Company’s restructuring. We expect to incur additional cash expenditures related to our planned facility exits and relocation activities, which will be recognized as incurred. We also may incur non-cash impairment charges as a result of exiting leased facilities if the carrying values of the related right-of-use asset balances and other related asset balances (e.g., leasehold improvements) will not be fully recoverable through our efforts to sublease an exited facility. We currently expect aggregate annualized cost savings from our 2023 Restructuring Plan to be between $45.0 and $55.0 million when completed.

### Other Strategic Business Decisions and Cost Saving Initiatives

#### Oqton

Throughout the six months ended June 30, 2024, the Company continued to evaluate strategic alternatives related to Oqton, Inc. ("Oqton") MOS, for which the Company previously disclosed during the year ended December 31, 2023 that it is more likely than not the business would be sold or otherwise disposed of. In connection with the expectation to sell or otherwise dispose of Oqton MOS, management previously assessed whether the carrying value of this asset group’s long-lived assets was recoverable, which resulted in a full impairment of the asset group's intangible assets during the year ended December 31, 2023. No incremental impairment charges have been recognized with respect to the carrying values of the asset group's other assets during the three or six months ended June 30, 2024. As a result of the impairment of Oqton MOS’s intangible assets during the year ended December 31, 2023, the Company has recognized lower amortization expense attributable to intangible assets for the three and six months ended June 30, 2024.

During May 2024, the Company completed the sale of the portion of the Oqton MOS business that was focused on the dental market ("Oqton Dental") in exchange for a de minimis amount of cash, resulting in the transfer of a limited portion of Oqton MOS's personnel and a de minimis amount of fixed assets. The sale of Oqton Dental does not qualify as a discontinued operation, as it does not represent a strategic shift that will have a major effect on our overall business operations; however, the transfer of personnel is expected to provide cost savings from the date of the disposal of Oqton Dental. The Company continues to evaluate strategic alternatives related to the remaining portion of Oqton MOS that the Company continues to hold.

#### Incremental Investment in NAMI

In May 2024, the Company made an incremental investment of $2.5 million in NAMI, the Company's joint venture with Dussur. Refer to Note 6 for additional details regarding this equity method investment.

### Investing in Regenerative Medicine

Within our Healthcare Solutions segment, a portion of our business focuses on opportunities for additive manufacturing to be applied to regenerative medicine. To date, our efforts in the area of regenerative medicine have consisted primarily of pre-commercial bio-technology research and development (“R&D”) in the areas described below.

Our first area of focus is the use of additive manufacturing for human organ transplantation, with a long-term goal of helping patients with end-stage disease receive transplants that will enable them to enjoy long and active lives. This program combines our 3D printing expertise and capabilities in human tissue engineering with the regenerative medicine and biotechnology expertise of a key strategic partner. Through the start of 2024, our program focused on developing the capability to print organ scaffolds for human lungs, kidneys and livers. However, beginning in the first quarter of 2024, due to changes to our arrangement with and funding from our key strategic partner, the Company’s continuing organ program shifted its focus to developing the capability to print human lung scaffolds, for which the related R&D efforts will continue to be primarily funded by our key strategic partner. Refer to Note 11 and Note 16 to the Financial Statements for additional information regarding the impact of the changes to this program.

Our second area of focus seeks to utilize our bio-printing capabilities to design and manufacture 3D-printed vascularized “organs-on-chips” for use in drug development by pharmaceutical industry customers through our wholly-owned biotech company, Systemic Bio. We believe that “organs-on-chips” can accelerate the drug development process and reduce the cost of pre-clinical drug testing, as well as reduce the pharmaceutical industry’s reliance on animal testing. Systemic Bio combines 3D Systems’ legacy expertise in high-resolution 3D printing with advanced capabilities in bioprinting and biomaterials to design and market 3D-printed, vascularized “organs-on-chips”. During the year ended December 31, 2023, Systemic Bio entered into its first commercial contracts with pharmaceutical industry customers.

#### Acquisition of Wematter (See Note 2 to the Financial Statements for further details)

On July 1, 2023, the Company completed the acquisition of Wematter AB (“Wematter”), a Swedish 3D printer manufacturer, for which post-acquisition results are included in our Industrial Solutions segment. The acquisition broadens 3D Systems’ Selective Laser Sintering (SLS) portfolio. Consideration for this acquisition consisted of approximately $10.2 million in cash, subject to customary post-closing adjustments. The Company also may be required to pay an additional €2.0 million in cash, contingent upon the achievement of certain post-closing performance conditions and the continued employment of certain key employees of Wematter for two years after the closing date of the acquisition. As of June 30, 2024, management does not believe that achievement of the post-closing performance conditions is probable.

### Background

We earn revenue from the sale of products and services through our Healthcare Solutions and Industrial Solutions segments. The product categories include 3D printers and corresponding materials, digitizers, software licenses, 3D scanners and haptic devices. The majority of materials used in our 3D printers are proprietary. The services categories include maintenance contracts and services on 3D printers, software maintenance, software as a service subscriptions and healthcare solutions services.

Given the relatively high price of certain 3D printers and a corresponding lengthy selling cycle, as well as relatively low unit volume of the higher-priced printers in any particular period, a shift in the timing and concentration of orders and shipments from one period to another can materially affect reported revenue in any given period.

In addition to changes in sales volumes, there are two other primary drivers of changes in revenue from one period to another: (1) the combined effect of changes in product mix and average selling prices and (2) the impact of fluctuations in foreign currencies. As used in this Management’s Discussion and Analysis of Financial Condition and Results of Operations ("MD&A"), the price and mix effects relate to changes in revenue that are not able to be specifically attributed to changes in unit volume or changes in foreign exchange rates.

### How We Assess the Performance of Our Business

We manage operations through the two business segments described above. In addition to our consolidated GAAP financial measures, we review Adjusted EBITDA.

We believe Adjusted EBITDA is a helpful supplemental measure to assist us and investors in evaluating our operating results, as Adjusted EBITDA excludes certain items for which the fluctuation from period to period does not necessarily correspond to changes in the operations of our business. Adjusted EBITDA represents net income (loss), plus income tax (provision) benefit, interest and other income (expense), net, stock-based compensation expense, amortization of intangible assets, depreciation expense, and certain other non-GAAP adjustments. We believe that the adjustments applied in presenting Adjusted EBITDA are appropriate to provide additional information to investors about our operating and financial performance without (1) the effect of certain material non-cash items and (2) certain items that we do not believe to be core to our operations.

Management and our Board of Directors regularly use Adjusted EBITDA in evaluating our operating and financial performance and in establishing discretionary annual compensation. This measure is provided in addition to, and should not be considered to be a substitute for, or superior to, comparable measures determined in accordance with GAAP. In addition, we believe that Adjusted EBITDA is frequently used by investors and other interested parties in the evaluation of other issuers, many of which also present Adjusted EBITDA when reporting their results in an effort to augment investors' understanding of their operating and financial results; however, similarly titled measures provided by other issuers may not be calculated in the same manner and/or using the same adjustments.

Adjusted EBITDA should not be considered as an alternative to net income (loss) or any other performance measure derived in accordance with GAAP. Adjusted EBITDA has limitations as an analytical tool, and you should not consider such measure either in isolation or as a substitute for analyzing our results as reported under GAAP.

For further information regarding Adjusted EBITDA, see “Reconciliation of non-GAAP Measures” below.

### Consolidated Financial Results for the Three and six Months Ended June 30, 2024 and 2023

*(in thousands)*

| Revenue: | Three Months Ended June 30, 2024 | June 30, 2023 | Six Months Ended June 30, 2024 | June 30, 2023 |
| --- | ---: | ---: | ---: | ---: |
| Products | $71,733 | $89,165 | $135,784 | $173,553 |
| Services | 41,519 | 39,029 | 80,373 | 75,877 |
| Total revenue | 113,252 | 128,194 | 216,157 | 249,430 |
| Cost of sales: |  |  |  |  |
| Products | 42,451 | 56,135 | 82,038 | 106,015 |
| Services | 23,703 | 22,043 | 46,099 | 46,301 |
| Total cost of sales | 66,154 | 78,178 | 128,137 | 152,316 |
| Gross profit | 47,098 | 50,016 | 88,020 | 97,114 |
| Operating expenses: |  |  |  |  |
| Selling, general and administrative | 51,494 | 58,983 | 108,798 | 117,268 |
| Research and development | 22,016 | 22,762 | 45,496 | 44,971 |
| Total operating expenses | 73,510 | 81,745 | 154,294 | 162,239 |
| Loss from operations | (26,412) | (31,729) | (66,274) | (65,125) |
| Interest and other income (expense), net: |  |  |  |  |
| Foreign exchange (loss) gain, net | (723) | (1,273) | 1,186 | (1,645) |
| Interest income | 1,452 | 5,343 | 4,250 | 9,889 |
| Interest expense | (624) | (939) | (1,338) | (1,680) |
| Other (expense) income, net | 384 | 83 | 21,770 | 525 |
| Total non-operating income | 489 | 3,214 | 25,868 | 7,089 |
| Loss before income taxes | (25,923) | (28,515) | (40,406) | (58,036) |
| Provision for income taxes | (476) | (222) | (1,847) | (230) |
| Loss on equity method investment, net of income taxes | (902) | (142) | (1,149) | (142) |
| Net loss before redeemable non-controlling interest | (27,301) | (28,879) | (43,402) | (58,408) |
| Less: net (loss) income attributable to redeemable non-controlling interest | (43) | 16 | (143) | (92) |
| Net loss attributable to 3D Systems Corporation | $(27,258) | $(28,895) | $(43,259) | $(58,316) |
| **Other Financial Data:** |  |  |  |  |
| Adjusted EBITDA | $(12,914) | $(6,898) | $(32,974) | $(16,993) |

32

### Consolidated Operating Results for the Three Months Ended June 30, 2024 Compared to the Three Months Ended June 30, 2023

#### Consolidated revenue

The following table sets forth changes in our products and services revenue for the three months ended June 30, 2024 and 2023.

*(Dollars in thousands)*

|  | Products |  | Services |  | Total |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue — three months ended June 30, 2023 | $89,165 | 69.6% | $39,029 | 30.4% | $128,194 | 100.0% |
| Change in revenue: |  |  |  |  |  |  |
| Volume | (13,400) | (15.0)% | 2,783 | 7.1% | (10,617) | (8.3)% |
| Price/mix | (3,298) | (3.7)% | — | —% | (3,298) | (2.6)% |
| Foreign currency translation | (734) | (0.8)% | (293) | (0.8)% | (1,027) | (0.8)% |
| Net change | (17,432) | (19.6)% | 2,490 | 6.3% | (14,942) | (11.7)% |
| Revenue — three months ended June 30, 2024 | $71,733 | 63.3% | $41,519 | 36.7% | $113,252 | 100.0% |

#### Products revenue

For the three months ended June 30, 2024, products revenue decreased by $17.4 million, or 19.6%, as compared to the three months ended June 30, 2023. This decrease is primarily attributable to lower sales volume. The $13.4 million, or 15.0%, decrease in products revenue due to lower sales volume reflects a $12.8 million decrease in revenue that is primarily attributable to lower printer and products sales and a $0.6 million decrease in revenue attributable to a lower volume of materials sales. Printer sales volume decreased for the three months ended June 30, 2024, compared to the three months ended June 30, 2023, due to (1) a significant decline in printer sales to our key customer in the dental industry, to which we also expect limited printer sales for the remainder of 2024, and (2) the general impact of macroeconomic conditions on printer sales more broadly across our business due to the capital expenditure nature of such customer purchases. Due to the high price of certain 3D printers, our total products revenue has been materially impacted by these period-over-period changes in the concentration of printer orders and shipments.

In addition, products revenue decreased $2.1 million due to the loss of revenue attributable to our regenerative medicine kidney and liver R&D program, as well as a decrease in revenue recognized related to our regenerative medicine lung R&D program due to less R&D activity performed during the three months ended June 30, 2024. Refer to the discussion of "Investing in Regenerative Medicine" within the "Recent Developments and Updates Regarding Strategic Initiatives" section of this MD&A for additional details regarding the change to our organs R&D program that resulted in the loss of revenue attributable to kidney and liver research.

A lower volume of materials sales contributed to a $0.6 million decrease in products revenue. This impact due to the change in the volume of materials sales reflects a significant increase in materials sold to our key customer in the dental industry, to which materials sales returned to normalized levels for the three months ended June 30, 2024, offset by lower volume of materials sales elsewhere in the business. During the three months ended June 30, 2023, we experienced lower volume of materials sales to our key customer in the dental industry due to the customer's higher inventory on hand during the period. During the three months ended June 30, 2024, materials sales were lower elsewhere in our business due to the slower sell through of inventory on-hand at certain customers.

Products revenue for the three months ended June 30, 2024 decreased $3.3 million due to changes in price/mix, which reflects an unfavorable impact of the increased sales of materials to our key customer in the dental industry at lower pricing as compared to the three months ended June 30, 2023.

#### Services revenue

For the three months ended June 30, 2024, services revenue increased by $2.5 million, or 6.3%, as compared to the three months ended June 30, 2023. This increase was primarily driven by increases in personalized healthcare services revenue, an increase in parts and maintenance revenue related to the installed printer base at our key dental industry customer, and revenue generated from a significant Industrial Solutions services contract that had not been executed as of June 30, 2023, partially offset by a decrease in parts manufacturing revenue recognized by our Healthcare Solutions segment during the three months ended June 30, 2024.

#### Total revenue

For the three months ended June 30, 2024, revenue decreased by $14.9 million, or 11.7%, as compared to the three months ended June 30, 2023. This decrease was primarily driven by the $17.4 million decrease in our products revenue, which was only partially offset by a $2.5 million increase in our services revenue. Refer to the discussions of products revenue and services revenue above for additional details.

#### Consolidated gross profit

*(Dollars in thousands)*

|  | Three Months Ended June 30, 2024 Gross Profit | Gross Profit Margin | June 30, 2023 Gross Profit | Gross Profit Margin | Change in Gross Profit $% |  | Change in Gross Profit Margin Percentage Points% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Products | $29,282 | 40.8% | 33,030 | 37.0% | $(3,748) | (11.3)% | 3.8 | 10.3% |
| Services | 17,816 | 42.9% | 16,986 | 43.5% | 830 | 4.9% | (0.6) | (1.4)% |
| Total | $47,098 | 41.6% | $50,016 | 39.0% | $(2,918) | (5.8)% | 2.6 | 6.7% |

#### Consolidated gross profit and gross profit margin

Our consolidated gross profit for the three months ended June 30, 2024 decreased $2.9 million, or 5.8%, to $47.1 million, as compared to $50.0 million for the three months ended June 30, 2023. Our consolidated gross profit margin increased to 41.6% for the three months ended June 30, 2024, as compared to 39.0% for the three months ended June 30, 2023.

Our consolidated gross profit was negatively impacted by the $14.9 million, or 11.7%, decrease in our consolidated revenue for the three months ended June 30, 2024. The decrease in our products revenue significantly exceeded the increase in our services revenue and, accordingly, the decrease in products gross profit due to lower products revenue was only partially offset by the increase in services gross profit attributable to higher services revenue.

Partially offsetting the decrease in our consolidated gross profit attributable to our lower reported revenue is the 260 basis point increase in our consolidated gross profit margin for the three months ended June 30, 2024. This increase in our consolidated gross profit margin for the three months ended June 30, 2024 was primarily driven by the significant increase in the gross profit margin realized on our products revenue, which was only partially offset by the decrease in the gross margin realized on our services revenue. Our consolidated gross profit margin also increased due to the increase in services revenue as a percentage of total revenue for the three months ended June 30, 2024, when compared to the products revenue versus services revenue mix for the three months ended June 30, 2023.

Refer to the discussions below for details regarding the factors that have impacted products and services gross profit and products and services gross profit margins for the three months ended June 30, 2024.

#### Products gross profit and gross profit margin

For the three months ended June 30, 2024, gross profit from products sales decreased by $3.7 million, or 11.3%, as compared to the three months ended June 30, 2023. This decrease in gross profit from products sales is primarily due to the $17.4 million, or 19.6% decrease in products revenue. Partially offsetting the impact of the lower products revenue for the three months ended June 30, 2024 is the 380 basis point increase in the gross profit margin realized on our products revenue. The most significant contributors to the increase in our products gross profit margin are (1) the increase in higher margin materials revenue as a percentage of our total products revenue and (2) the impact of the Company's adjustment to its estimate of severance related costs.

#### Services gross profit and gross profit margin

For the three months ended June 30, 2024, gross profit from services sales increased $0.8 million, or 4.9%, as compared to the three months ended June 30, 2023. The increase in services gross profit for the three months ended June 30, 2024 is primarily due to the $2.5 million, or 6.3%, increase in services revenue for the three months ended June 30, 2024. Partially offsetting the impact of the higher services revenue for the three months ended June 30, 2024 is the 60 basis point decrease in the gross profit margin realized on our services revenue. This decrease in realized services gross profit margin was primarily due to cost inflation.

#### Consolidated selling, general and administrative expense

Selling, general and administrative ("SG&A") expense for the three months ended June 30, 2024 decreased $7.5 million, or 12.7%, to $51.5 million, as compared to $59.0 million for the three months ended June 30, 2023. The primary drivers of the $7.5 million decrease in SG&A expense reported for the three months ended June 30, 2024 are as follows:

| Primary drivers (in thousands) | Increase / (Decrease) |
| --- | ---: |
| Compensation and benefits | $(6,495) |
| Amortization expense | (1,052) |
| Volumetric earnout | 978 |
| Audit, legal and third-party consulting costs | 226 |
| Other | (1,146) |
| Total change | $(7,489) |

#### Compensation expense and benefits

Compensation and benefits expense decreased by $6.5 million for the three months ended June 30, 2024, as compared to the three months ended June 30, 2023. This decrease was primarily driven by a $4.5 million decrease in stock-based and bonus incentive compensation expense and a $1.6 million decrease in severance expense. The decrease in stock-based compensation expense for the three months ended June 30, 2024 is primarily due to (1) the reversal of previously recognized expense as a result of the current period forfeitures of a significant volume of unvested awards that were held by employees terminated under the Company's 2023 Restructuring Plan and (2) the delayed grant of fiscal year 2024 annual share-based payment awards, which will not occur until after the Company holds its annual stockholder meeting, assuming the Company's stockholders approve the Company's amended and restated 2015 Incentive Plan. The decrease in stock-based compensation expense related to award forfeitures and delayed grants of new stock-based compensation awards during fiscal year 2024 has been partially offset by a significant increase in stock-based compensation expense recognized under the Company's separate Systemic Bio Phantom Unit Plan, as well as the accelerated vesting of shares that will be granted to settle the Company's dp polar earnout obligation. Refer to Note 11 to the Financial Statements for additional details regarding stock-based compensation recognized under the Company's Systemic Bio Phantom Unit Plan and related to the dp polar earnout.

Cash bonus expense for the three months ended June 30, 2024 and June 30, 2023 reflects the amount of cash bonus compensation required to be recognized to appropriately report the Company's bonus liability as of each respective balance sheet date. The liability reported as of each balance sheet date is based upon management's estimate of annualized bonus expense after consideration of the Company's performance relative to annual performance targets established under the bonus plan. Cash bonus expense recognized for the three months ended June 30, 2024 decreased as compared to the three months ended June 30, 2023 based upon management's estimates of fiscal year 2024 and fiscal year 2023 annual bonus expense as of the respective balance sheet dates.

The decrease in severance expense recognized for the three months ended June 30, 2024, as compared to the three months ended June 30, 2023, is due to the recognition of significantly higher severance and termination benefit charges under our 2023 Restructuring Plan during the prior year period. Under our 2023 Restructuring Plan, employee severance and termination benefit costs are generally recognized when probable and estimable because they are typically being determined consistent with the Company’s past practices or statutory law.

#### Amortization expense

Amortization expense decreased by $1.1 million for the three months ended June 30, 2024 due to the impairment charges that reduced the carrying values of intangible assets included in the Oqton MOS and dp polar asset groups to $0 during the three months ended September 30, 2023 and December 31, 2023, respectively. Refer to the discussion of "Other Strategic Business Decisions and Cost Saving Initiatives" within the "Recent Developments and Updates Regarding Strategic Initiatives" section of this MD&A for additional details regarding the Company's recent actions taken with respect Oqton. Amortization expense attributable to intangible assets recorded in connection with the Company's July 1, 2023 acquisition of Wematter partially offset the lower amortization expense resulting from the impairment of the intangible asset balances previously included in the Oqton MOS and dp polar asset groups.

#### Volumetric earnout

For the three months ended June 30, 2023, the Company recognized a reversal of a portion of the previously accrued Volumetric earnout expense, as compared to the recognition of no expense for the three months ended June 30, 2024. The reversal of Volumetric expense in the prior year period was due to an increase in the estimated amount of time that it would take the Company to the achieve the non-financial, scientific milestone that would trigger the $65 million earnout payment that the Company had previously concluded was probable of becoming due in the future. During the quarter ended September 30, 2023, the Company ceased the recognition of compensation expense related to this potential $65 million earnout payment and reversed all compensation expense that previously had been recognized, as the Company concluded that the non-financial, science-based milestone to which the earnout payment related was no longer probable of being achieved given a reduction in the budgeted funding for the related R&D efforts. Furthermore, as a result of events that occurred during the six months ended June 30, 2024, the Company has notified the sellers of Volumetric that they are no longer eligible to earn any of the milestone-based earnout payments contemplated in the Volumetric acquisition agreement. Refer to the discussions in Note 11 and Note 16 to the Financial Statements, for additional details regarding the Company's cancellations of the Volumetric sellers' rights to future earnout payments, as well as actions taken in response to these cancellations.

#### Audit, legal and third-party consulting costs

Audit, legal and third-party consulting costs increased $0.2 million for the three months ended June 30, 2024 primarily due to significant increases in the cost to complete our fiscal year 2023 audit, including costs paid to our former independent registered public accounting firm, third-party accounting and finance consulting support costs, and costs incurred in connection with the Company's export control remedial compliance activities undertaken in lieu of payment of an additional settlement amount under the agreement reached with the DDTC in February 2023 (Refer to Note 16 to the Financial Statements). The increases in audit, third-party accounting support, and compliance costs were significantly offset by reductions in litigation and acquisition related legal costs. In addition, we incurred a significant amount of costs for the three months ended June 30, 2023 relating to our restructuring and finance transformation efforts that were not incurred in the three months ended June 30, 2024.

#### Consolidated research and development expense

R&D expense for the three months ended June 30, 2024 decreased $0.8 million, or 3.3%, to $22.0 million as compared to $22.8 million for the three months ended June 30, 2023. This decrease in R&D expense was primarily driven by cost savings realized under the Company's 2023 Restructuring Plan. Partially offsetting the cost savings from the Company's 2023 Restructuring Plan are increases in R&D costs related to (1) the year-over-year ramp up of activities performed by our wholly-owned bio-tech subsidiary, Systemic Bio, which is focused on the design and manufacture of 3D-printed vascularized “organs-on-chips” for use in drug development by pharmaceutical industry customers and (2) R&D costs attributable to Wematter, which we acquired subsequent to the six months ended June 30, 2023. Refer to the discussions of "Investing in Regenerative Medicine" and "Acquisitions" in the "Recent Developments and Updates Regarding Strategic Initiatives" section of this MD&A for additional details regarding Systemic Bio and the Wematter acquisition. Further offsetting the cost savings from the Company's 2023 Restructuring Plan is R&D expense that continued to be incurred related to the kidney and liver regenerative medicine R&D program (1) after the focus of the Company's organ program with its strategic partner shifted solely to developing the capability to print lung scaffolds and (2) prior to fully winding down or reallocating the resources that had been committed to the kidney and liver program.

#### Consolidated operating loss

Our operating loss for the three months ended June 30, 2024 was $26.4 million, as compared to a $31.7 million operating loss for the three months ended June 30, 2023. Our reported operating loss for the three months ended June 30, 2024 decreased as the aggregate impacts of the increase in our gross profit realized on services revenue and decreases in reported SG&A expense and R&D expense exceeded the decrease in our gross profit resulting from our lower reported products revenue. Refer to the revenue, gross profit and cost discussions above for additional details.

### Consolidated Operating Results for the Six Months Ended June 30, 2024 Compared to the Six Months Ended June 30, 2023

The following table sets forth changes in our products and services revenue for the six months ended June 30, 2024 and 2023.

*(Dollars in thousands)*

|  | Products |  | Services |  | Total |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue — six months ended June 30, 2023 | $173,553 | 69.6% | $75,877 | 30.4% | $249,430 | 100.0% |
| Change in revenue: |  |  |  |  |  |  |
| Volume | (33,403) | (19.2)% | 4,770 | 6.3% | (28,633) | (11.5)% |
| Price/mix | (3,597) | (2.1)% | 1 | —% | (3,596) | (1.4)% |
| Foreign currency translation | (769) | (0.4)% | (275) | (0.4)% | (1,044) | (0.4)% |
| Net change | (37,769) | (21.8)% | 4,496 | 5.9% | (33,273) | (13.3)% |
| Revenue — six months ended June 30, 2024 | $135,784 | 62.8% | $80,373 | 37.2% | $216,157 | 100.0% |

#### Products revenue

For the six months ended June 30, 2024, products revenue decreased by $37.8 million, or 21.8%, as compared to the six months ended June 30, 2023. This decrease is primarily attributable to lower sales volume. The $33.4 million, or 19.2%, decrease in products revenue due to lower sales volume reflects a $38.0 million decrease in revenue that is primarily attributable to a lower volume of printer and other products sales, partially offset by a $4.6 million increase in revenue attributable to a higher volume of materials sales. Printer sales volume decreased for the six months ended June 30, 2024 compared to the six months ended June 30, 2023 due to (1) a significant decline in printer sales to our key customer in the dental industry, to which we also expect limited printer sales for the remainder of 2024, and (2) the general impact of macroeconomic conditions on printer sales more broadly across our business due to the capital expenditure nature of such customer purchases. Due to the high price of certain 3D printers, our total products revenue has been materially impacted by these period-over-period changes in the concentration of printer orders and shipments.

In addition, printer and products revenue decreased $4.9 million due to the loss of revenue attributable to our regenerative medicine kidney and liver R&D program, as well as lower revenue recognized related to our regenerative medicine lung R&D program due to less R&D activity performed during the six months ended June 30, 2024. Refer to the discussion of "Investing in Regenerative Medicine" within the "Recent Developments and Updates Regarding Strategic Initiatives" section of this MD&A for additional details regarding the change to our organs R&D program that resulted in the loss of revenue attributable to kidney and liver research.

The decrease in products revenue attributable to the lower volume of printer sales and the decrease in R&D activity performed under our regenerative medicine organ program was partially offset by a $4.6 million increase in revenue attributable to a higher volume of materials sales. This increase in volume was primarily driven by increased materials sales to our key customer in the dental industry, which returned to normalized levels for the six months ended June 30, 2024. During the six months ended June 30, 2023, we experienced significantly lower materials sales to this key customer due to the customer's higher inventory on hand during the period. The higher volume of materials sales to our key customer in the dental industry were partially offset by lower materials sales volume elsewhere in our business, largely driven by slower sell through of materials inventory at certain customers.

Products revenue for the six months ended June 30, 2024 decreased $3.6 million due to changes in price/mix, which primarily reflects an unfavorable impact of the increased sales of materials to our key customer in the dental industry at lower pricing as compared to the six months ended June 30, 2023. As materials sales volume decreased elsewhere in our business, materials sales to this key customer in the dental industry also represented a higher percentage of our total materials sales.

#### Services revenue

For the six months ended June 30, 2024, services revenue increased by $4.5 million, or 5.9%, as compared to the six months ended June 30, 2023. This increase was primarily driven by increases in personalized healthcare services revenue, an increase in parts and maintenance revenue related to the installed printer base at our key dental industry customer, and revenue generated from a significant Industrial Solutions services contract that had not been executed as of June 30, 2023, partially offset by a decrease in parts manufacturing revenue recognized by our Healthcare Solutions segment during the six months ended June 30, 2024.

#### Total revenue

For the six months ended June 30, 2024, revenue decreased by $33.3 million, or 13.3%, as compared to the six months ended June 30, 2023. This decrease was primarily driven by the $37.8 million decrease in our products revenue, which was only partially offset by a $4.5 million increase in our services revenue. Refer to the discussions of products revenue and services revenue above for additional details.

#### Consolidated gross profit

*(Dollars in thousands)*

|  | Six Months Ended June 30, 2024 Gross Profit | Gross Profit Margin | June 30, 2023 Gross Profit | Gross Profit Margin | Change in Gross Profit $% |  | Change in Gross Profit Margin Percentage Points% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Products | $53,746 | 39.6% | 67,538 | 38.9% | $(13,792) | (20.4)% | 0.7 | 1.8% |
| Services | 34,274 | 42.6% | 29,576 | 39.0% | 4,698 | 15.9% | 3.6 | 9.2% |
| Total | $88,020 | 40.7% | $97,114 | 38.9% | $(9,094) | (9.4)% | 1.8 | 4.6% |

#### Consolidated gross profit and gross profit margin

Our consolidated gross profit for the six months ended June 30, 2024 decreased $9.1 million, or 9.4%, to $88.0 million, as compared to $97.1 million for the six months ended June 30, 2023. Our consolidated gross profit margin increased to 40.7% for the six months ended June 30, 2024, as compared to 38.9% for the six months ended June 30, 2023.

Our consolidated gross profit was negatively impacted by the $33.3 million, or 13.3%, decrease in our consolidated revenue for the six months ended June 30, 2024. The decrease in our products revenue significantly exceeded the increase in our services revenue and, accordingly, the decrease in products gross profit due to lower products revenue was only partially offset by the increase in services gross profit attributable to higher services revenue.

Partially offsetting the decrease in our consolidated gross profit attributable to lower consolidated revenue is the 180 basis point increase in our consolidated gross profit margin for the six months ended June 30, 2024. This increase in our consolidated gross profit margin for the six months ended June 30, 2024 was driven by the significant increase in the gross profit margin realized on our services revenue, as well as the increase in services revenue as a percentage of total revenue, when compared to the products revenue versus services revenue mix for the six months ended June 30, 2023.

Refer to the discussions below for details regarding the factors that have impacted products and services gross profit and products and services gross profit margins for the six months ended June 30, 2024.

#### Products gross profit and gross profit margin

For the six months ended June 30, 2024, gross profit from products sales decreased by $13.8 million, or 20.4%, as compared to the six months ended June 30, 2023. This decrease in gross profit from products sales is primarily due to the $37.8 million, or 21.8% decrease in products sales revenue. Our gross profit margin improved to 39.6% for the six month periods ended June 30, 2024 compared to 38.9% for the six months ended June 30, 2023, respectively, due to the reduction of previously accrued severance.

#### Services gross profit and gross profit margin

For the six months ended June 30, 2024, gross profit from services sales increased $4.7 million, or 15.9%, as compared to the six months ended June 30, 2023. The increase in services gross profit for the six months ended June 30, 2024 was driven by a $4.5 million, or 5.9%, increase in our reported services revenue, as well as a 360 basis point increase in services gross profit margin. The increase in services gross profit margin was due to a more favorable sales mix for the six months ended June 30, 2024 compared to June 30, 2023.

#### Consolidated selling, general and administrative expense

SG&A expense for the six months ended June 30, 2024 decreased $8.5 million, or 7.2%, to $108.8 million, as compared to $117.3 million for the six months ended June 30, 2023. The primary drivers of the $8.5 million decrease in SG&A expense reported for the six months ended June 30, 2024 are as follows:

| Primary drivers (in thousands) | Increase / (Decrease) |
| --- | ---: |
| Compensation and benefits | $(7,736) |
| Volumetric earnout | (3,002) |
| Amortization expense | (2,121) |
| Audit, legal and third-party consulting costs | 5,648 |
| Accrued contingency expense | 1,750 |
| Other | (3,009) |
| Total change | $(8,470) |

#### Compensation and Benefits

Compensation and benefits expense decreased by $7.7 million for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023. This decrease was primarily driven by a $4.4 million decrease in stock-based and bonus incentive compensation expense and a $2.8 million decrease in severance expense. The decrease in stock-based compensation expense for the six months ended June 30, 2024 is primarily due to (1) the reversal of previously recognized expense as a result of the current period forfeitures of a significant volume of unvested awards that were held by employees terminated under the Company's 2023 Restructuring Plan and (2) the Company's delayed granting of fiscal year 2024 annual share-based payment awards, which will not occur until after the Company holds its annual stockholder meeting, assuming the Company's stockholders approve the Company's amended and restated 2015 Incentive Plan. The decrease in stock-based compensation expense related to award forfeitures and delayed grants of new stock-based compensation awards during fiscal year 2024 has been partially offset by a significant increase in stock-based compensation expense recognized under the Company's separate Systemic Bio Phantom Unit Plan, as well as the accelerated vesting of shares that will be granted to settle the Company's dp polar earnout obligation. Refer to Note 11 to the Financial Statements for additional details regarding stock-based compensation recognized under the Company's Systemic Bio Phantom Unit Plan and related to the dp polar earnout.

Cash bonus expense for the six months ended June 30, 2024 and June 30, 2023 reflects the amount of cash bonus compensation required to be recognized to appropriately report the Company's bonus liability as of each respective balance sheet date. The liability reported as of each balance sheet date is based upon management's estimate of annualized bonus expense after consideration of the Company's performance relative to annual performance targets established under the bonus plan. Cash bonus expense recognized for the six months ended June 30, 2024 decreased as compared to the six months ended June 30, 2023 based upon management's estimates of fiscal year 2024 and fiscal year 2023 annual bonus expense as of the respective balance sheet dates.

The decrease in severance expense recognized for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023, is due to the recognition of significantly greater severance and termination benefit charges under our 2023 Restructuring Plan during the prior year period. Under our 2023 Restructuring Plan, employee severance and termination benefit costs are generally recognized when probable and estimable because they are typically being determined consistent with the Company’s past practices or statutory law.

#### Volumetric earnout

Volumetric earnout expense decreased by $3.0 million for the six months ended June 30, 2024 as the Company is no longer accruing compensation expense related to a $65 million earnout payment that was potentially payable to the sellers of Volumetric pursuant to the terms of the Volumetric acquisition agreement. However, during the six months ended June 30, 2023, the Company was accruing compensation expense related to this potential earnout payment as the conditions for payment were deemed probable of achievement. During the quarter ended September 30, 2023, the Company concluded that the non-financial, science-based milestone to which the potential earnout payment of $65 million related was no longer probable of being achieved due to a reduction in the budgeted funding for the related R&D efforts. Accordingly, all previously recognized compensation expense was reversed as of September 30, 2023, and the Company has ceased recognizing earnout compensation expense for all reporting periods occurring thereafter. Furthermore, as a result of events that have occurred during the six months ended June 30, 2024, the Company has notified the sellers of Volumetric that they are no longer eligible to earn any of the milestone-based earnout payments contemplated in the Volumetric acquisition agreement. Refer to the discussions in Note 11 and Note 16 to the Financial Statements, for additional details regarding the Company's cancellations of the Volumetric sellers' rights to future earnout payments, as well as actions taken in response to these cancellations.

#### Amortization expense

Amortization expense decreased by $2.1 million for the six months ended June 30, 2024 due to the impairment charges that reduced the carrying values of intangible assets included in the Oqton MOS and dp polar asset groups to $0 during the three months ended September 30, 2023 and December 31, 2023, respectively. Refer to the discussion of "Other Strategic Business Decisions and Cost Saving Initiatives" within the "Recent Developments and Updates Regarding Strategic Initiatives" section of this MD&A for additional details regarding the Company's recent actions taken with respect Oqton. Amortization expense attributable to intangible assets recorded in connection with the Company's July 1, 2023 acquisition of Wematter partially offset the lower amortization expense resulting from the impairment of the intangible asset balances previously included in the Oqton MOS and dp polar asset groups.

#### Audit, legal and third-party consulting costs

Audit, legal and third-party consulting costs increased $5.6 million for the six months ended June 30, 2024 primarily due to significant increases in the cost to complete our fiscal year 2023 audit, including costs paid to our former independent registered public accounting firm, third-party accounting and finance consulting support costs, and costs incurred in connection with the Company's export control remedial compliance activities undertaken in lieu of payment of an additional settlement amount under the agreement reached with the DDTC in February 2023 (Refer to Note 16 to the Financial Statements). Partially offsetting the increases in expense discussed above, we incurred lower costs attributable to certain finance transformation activities for the six months ended June 30, 2024 compared to the six months ended June 30, 2023.

#### Accrued contingency expense

Accrued contingency expense increased due to the accrual of $1.8 million relating to a proposed settlement with the former shareholders and key employees of Volumetric during mediation. Refer to Note 16 to the Financial Statements for additional details regarding the ongoing mediation with the former shareholders and key employees of Volumetric.

#### Consolidated research and development expense

R&D expense for the six months ended June 30, 2024 increased $0.5 million, or 1.2%, to $45.5 million as compared to $45.0 million for the six months ended June 30, 2023. This increase in R&D expense was partially due to (1) the year-over-year ramp up of activities performed by our wholly-owned bio-tech subsidiary, Systemic Bio, which is focused on the design and manufacture of 3D-printed vascularized “organs-on-chips” for use in drug development by pharmaceutical industry customers and (2) R&D costs attributable to Wematter, which we acquired subsequent to the six months ended June 30, 2023. Refer to the discussions of "Investing in Regenerative Medicine" and "Acquisitions" in the "Recent Developments and Updates Regarding Strategic Initiatives" section of this MD&A for additional details regarding Systemic Bio and the Wematter acquisition. In addition, the increase in reported R&D expense is partially due to R&D expense that continued to be incurred related to the kidney and liver regenerative medicine R&D program (1) after the focus of the Company's organ program with its strategic partner shifted solely to developing the capability to print lung scaffolds and (2) prior to fully winding down or reallocating the resources that had been committed to the kidney and liver program. Offsetting the increases to R&D costs noted above are cost savings attributable to the Company's 2023 Restructuring Plan.

#### Consolidated operating loss

Our operating loss for the six months ended June 30, 2024 was $66.3 million, as compared to a $65.1 million operating loss for the six months ended June 30, 2023. The increase in our operating loss for the six months ended June 30, 2024 is due to lower products revenue, resulting in lower related gross profit, and higher R&D costs. The decrease in gross profit from product sales and increase in R&D costs were partially offset by an increase in services revenue and related gross profit and lower SG&A costs. Refer to the revenue, gross profit, and cost discussions above for additional details.

### Non-Operating Income (Loss) for the Three and Six Months Ended June 30, 2024 compared to the Three and Six Months Ended June 30, 2023

#### Other income, net

The following table sets forth the components of non-operating income for the three and six months ended June 30, 2024 and 2023.

*(in thousands)*

| Non-operating income (expense): | Three Months Ended June 30, 2024 | June 30, 2023 | Six Months Ended June 30, 2024 | June 30, 2023 |
| --- | ---: | ---: | ---: | ---: |
| Foreign exchange (loss) gain, net | $(723) | $(1,273) | $1,186 | $(1,645) |
| Interest income | 1,452 | 5,343 | 4,250 | 9,889 |
| Interest expense | (624) | (939) | (1,338) | (1,680) |
| Other income, net | 384 | 83 | 21,770 | 525 |
| Total non-operating income | $489 | $3,214 | $25,868 | $7,089 |

#### Interest income

For the three and six months ended June 30, 2024, interest income decreased as compared to the three and six months ended June 30, 2023 due to the Company's lower cash and cash equivalent balances during and as of three and six months ended June 30, 2024.

#### Interest expense

For the three and six months ended June 30, 2024, interest expense decreased as compared to the three and six months ended June 30, 2023 due to the Company's repurchases of debt in December of 2023 and March of 2024. In connection with each of these repurchases of debt, the Company wrote off a portion of the unamortized debt issuance costs, which resulted in lower amortization of debt issuance costs and, accordingly, interest expense for the three and six months ended June 30, 2024.

#### Other income, net

For the three months ended June 30, 2024, other income, net was relatively flat as compared to the three months ended June 30, 2023. For the six months ended June 30, 2024, other income, net increased, as compared to the six months ended June 30, 2023, primarily due to the recognition of a $21.5 million gain on the extinguishment of debt during the six months ended June 30, 2024.

#### Net loss

The following table sets forth the net loss attributable to 3D Systems Corporation for the three and six months ended June 30, 2024 and 2023.

*(in thousands, except per share amounts)*

|  | Three Months Ended June 30, 2024 | June 30, 2023 | Six Months Ended June 30, 2024 | June 30, 2023 |
| --- | ---: | ---: | ---: | ---: |
| Loss before income taxes | $(25,923) | $(28,515) | $(40,406) | $(58,036) |
| Provision for income taxes | (476) | (222) | (1,847) | (230) |
| Loss on equity method investment, net of income taxes | (902) | (142) | (1,149) | (142) |
| Net loss before redeemable non-controlling interest | (27,301) | (28,879) | (43,402) | (58,408) |
| Less: net (loss) income attributable to redeemable non-controlling interest | (43) | 16 | (143) | (92) |
| Net loss attributable to 3D Systems Corporation | $(27,258) | $(28,895) | $(43,259) | $(58,316) |
| Net loss per common share: |  |  |  |  |
| Basic | $(0.21) | $(0.22) | $(0.33) | $(0.45) |
| Diluted | $(0.21) | $(0.22) | $(0.33) | $(0.45) |

#### Provision for income taxes

Our tax provision for the three months ended June 30, 2024 was $0.5 million as compared to $0.2 million for the three months ended June 30, 2023. Taxes reported for the three months ended June 30, 2024 and June 30, 2023 were (1) de minimis, (2) provisions, rather than tax benefits, and (3) significantly below both our U.S. and foreign jurisdictions' statutory rates due to the Company's reported losses and the recognition of valuation allowances against the resulting deferred tax assets in the jurisdictions where the losses have occurred.

Our tax provision for the six months ended June 30, 2024 was $1.8 million, as compared to $0.2 million for the six months ended June 30, 2023. Taxes reported for the six months ended June 30, 2024 and June 30, 2023 were (1) de minimis, (2) provisions, rather than tax benefits, and (3) significantly below both our U.S. and foreign jurisdictions' statutory rates due to the Company's reported losses and the recognition of valuation allowances against the resulting deferred tax assets in the jurisdictions where the losses have occurred. The increase in our tax provision for the six months ended June 30, 2024 was due to increased valuation allowances recorded at certain foreign entities during the period to eliminate the previously anticipated benefit of our deferred tax assets recorded at these entities.

#### Loss on equity method investment, net of income taxes

We hold a 49% investment ownership interest in a joint venture, NAMI, that we account for under the equity method of accounting. (Refer to Note 6 to the Financial Statements for further details.) Under the equity method of accounting, we recognize our proportionate share of NAMI's reported net income or reported net losses ("equity method income" or "equity method losses", respectively) on a one quarter lag, and we defer the recognition of 49% of intra-entity profits related to products that the Company has sold to NAMI that continue to remain on NAMI's balance sheet. The increase in the reported loss on equity method of investment for both the three and six months ended June 30, 2024, as compared to the three and six months ended June 30, 2023, primarily reflects increased losses reported by NAMI and our application of the equity method of accounting to this investment. In addition, our reported loss on equity method investment for the six months ended June 30, 2024 reflects the recognition of equity method losses for a six-month period; whereas, for the six months ended June 30, 2023, we did not commence the recognition of equity method losses until April 1, 2023 due to the timing of our investment in this joint venture and our recognition of equity method losses on a one quarter lag.

#### Net loss attributable to 3D Systems Corporation

Our reported net loss attributable to 3D Systems Corporation remained relatively unchanged for the three months ended June 30, 2024, as compared to the three months ended June 30, 2023. Although our loss from operations decreased by $5.3 million for the three months ended June 30, 2024, this decrease was substantially offset by the $2.7 million decrease in our non-operating income and the $0.8 million increase in our loss on equity method investment for the three months ended June 30, 2024, as compared to the three months ended June 30, 2023. Refer to the discussions above for details regarding the factors that contributed to our lower reported loss from operations, lower reported non-operating income, and higher loss on equity method investment for the three months ended June 30, 2024.

Our reported net loss attributable to 3D Systems Corporation decreased $15.1 million for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023. This decrease in our reported loss was primarily driven by an $18.8 million increase in our non-operating income for the six months ended June 30, 2024, which is mainly attributable to the $21.5 million gain recognized on debt extinguishment during the period. Partially offsetting the increase in our non-operating income for the six months ended June 30, 2024 are a $1.1 million increase in our loss from operations, $1.6 million increase in our income tax provision, and a $1.0 million increase in our loss on equity method investment, net of income taxes for the period. Refer to the discussions above for details regarding the factors that contributed to our higher reported loss from operations, higher tax provision, higher loss on equity method investment, and higher reported non-operating income for the six months ended June 30, 2024.

### Non-GAAP Earnings

#### Adjusted EBITDA

Our Adjusted EBITDA decreased from negative $6.9 million for the three months ended June 30, 2023 to negative $12.9 million for the three months ended June 30, 2024. This decrease in our Adjusted EBITDA is the result of the decrease in our reported revenue for the three months ended June 30, 2024, which was not offset by an equivalent decrease in our core operating costs. Although our reported operating loss improved by $5.3 million for the three months ended June 30, 2024, as compared to the three months ended June 30, 2023, our reported operating losses for each period include certain non-cash and certain non-core operating expenses that are excluded from the determination of Adjusted EBITDA. For the three months ended June 30, 2024, amounts incurred for (1) non-cash depreciation expense, amortization expense, and stock-based compensation expense and (2) non-core acquisition and divestiture expense, legal and other related costs, and restructuring expense were significantly less than amounts incurred for the three months ended June 30, 2023. Accordingly, after adjustment of our GAAP results for these non-cash and non-core operating costs incurred in each period, our Adjusted EBITDA decreased by $6.0 million for the three months ended June 30, 2024, notwithstanding the improvement in our reported operating income. Refer to the reconciliation of our reported Net Loss to Adjusted EBITDA (below) for additional details regarding the amounts incurred related to non-cash and non-core operating expenses, as well as amounts incurred related to non-operating expenses, during the three months ended June 30, 2024 and June 30, 2023.

Our Adjusted EBITDA decreased from negative $17.0 million for the six months ended June 30, 2023 to negative $33.0 million for the six months ended June 30, 2024. This decrease in our Adjusted EBITDA is the result of the decrease in our reported revenue for the six months ended June 30, 2024, which was not offset by an equivalent decrease in our core operating costs. Although our reported operating loss only increased by $1.1 million for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023, our reported operating losses for each period include certain non-cash and certain non-core operating expenses that are excluded from the determination of Adjusted EBITDA. For the six months ended June 30, 2024, amounts incurred for (1) non-cash depreciation expense, amortization expense, and stock-based compensation expense and (2) non-core acquisition and divestiture expenses and restructuring expense were significantly less than amounts incurred for the six months ended June 30, 2023. Accordingly, after adjustment of our GAAP results for these non-cash and non-core operating costs incurred in each period, our Adjusted EBITDA decreased by $16.0 million for the six months ended June 30, 2024. Refer to the reconciliation of our reported Net Loss to Adjusted EBITDA (below) for additional details regarding the amounts incurred related to non-cash and non-core operating expenses, as well as amounts incurred related to non-operating expenses, during the six months ended June 30, 2024 and June 30, 2023.

#### Reconciliation of Non-GAAP Measures

The table that follows provides a reconciliation of the Company's reported Net Loss to Adjusted EBITDA. Refer to the discussion of "How We Assess the Performance of Our Business" for additional information regarding Adjusted EBITDA, and why management believes this measure provides useful information regarding the Company's results of operations.

*(in thousands)*

|  | Three Months Ended June 30, 2024 | June 30, 2023 | Six Months Ended June 30, 2024 | June 30, 2023 |
| --- | ---: | ---: | ---: | ---: |
| Net Loss | $(27,258) | $(28,895) | $(43,259) | $(58,316) |
| Interest (income) expense, net | (828) | (4,404) | (2,912) | (8,209) |
| Provision (benefit) for income taxes | 476 | 222 | 1,847 | 230 |
| Depreciation expense | 4,910 | 5,294 | 9,870 | 10,606 |
| Amortization expense | 2,589 | 3,258 | 4,902 | 6,497 |
| Stock-based compensation expense | 3,389 | 7,990 | 11,574 | 18,282 |
| Acquisition and divestiture-related expense | 181 | 1,512 | 234 | 4,188 |
| Legal and other related costs | 2,342 | 2,656 | 6,582 | 2,735 |
| Restructuring expense | 87 | 4,121 | 138 | 5,824 |
| Redeemable non controlling interest | (43) | 16 | (143) | (92) |
| Loss on equity method investments, net of tax | 902 | 142 | 1,149 | 142 |
| Gain on repurchase of debt | — | — | (21,518) | — |
| Other non-operating (income) expense, net | 339 | 1,190 | (1,438) | 1,120 |
| Adjusted EBITDA | $(12,914) | $(6,898) | $(32,974) | $(16,993) |

### Segment Financial Results for the Three Months Ended June 30, 2024 and 2023

The Company has two reportable segments: Healthcare Solutions and Industrial Solutions. Our reportable segments are based upon the industry verticals that they serve and reflect how we report our financial results to the Company's chief operating decision maker ("CODM").

Our CODM evaluates the performance of our reportable segments based upon Segment Revenue and Segment Adjusted EBITDA. Segment Adjusted EBITDA excludes (1) expenses related to corporate functions such as human resources, finance, and legal, inclusive of salaries, benefits, and other related costs, and (2) the non-cash and non-core operating expenses and non-operating income and expenses that we exclude from our calculation of consolidated Adjusted EBITDA (as reflected in our reconciliation of our consolidated Net Loss to Adjusted EBITDA above). Unallocated corporate expenses are not discussed separately as any variances that had a significant impact on our operating results for the three months and six months ended June 30, 2024, as compared to the three and six months ended June 30, 2023, are addressed in the discussions of our “Consolidated Operating Results for the Three Months Ended June 30, 2024 Compared to the Three Months Ended June 30, 2023” and “Consolidated Operating Results for the Six Months Ended June 30, 2024 Compared to the Six Months Ended June 30, 2023” included above.

The following table presents revenue and Adjusted EBITDA for our Healthcare Solutions segment and our Industrial Solutions segment for the three months ended June 30, 2024 and 2023:

*(in thousands)*

|  | Segment Revenue Three Months Ended June 30, 2024 | June 30, 2023 | Change | Segment Adjusted EBITDA Three Months Ended June 30, 2024 | June 30, 2023 | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Healthcare Solutions | $48,900 | $60,874 | $(11,974) | $8,772 | $11,394 | $(2,622) |
| Industrial Solutions | 64,352 | 67,320 | (2,968) | 3,358 | 2,264 | 1,094 |
| Total Segment Results | $113,252 | $128,194 | $(14,942) | $12,130 | $13,658 | $(1,528) |

### Healthcare Solutions

#### Revenue

For the three months ended June 30, 2024, Healthcare Solutions revenue decreased $12.0 million, or 19.7%, as compared to the three months ended June 30, 2023. This decrease in segment revenue was driven by a $12.8 million decrease in products revenue, consisting of revenue from printers, products and materials sales, partially offset by a $0.8 million increase in services revenue.

For the three months ended June 30, 2024, the $12.8 million decrease in Healthcare Solutions products revenue was primarily driven by an $8.6 million decrease in revenue attributable to lower sales volume and a $4.0 million decrease in revenue attributable the unfavorable impact of price/mix. The $8.6 million decrease in revenue attributable to lower sales volume reflects a $13.4 million decrease in printer and products revenue due to lower sales volume, which was only partially offset by a $4.8 million increase in materials revenue due to higher sales volume. For the three months ended June 30, 2024, a significant decline in printer sales to our key customer in the dental industry was the largest contributor to the lower printer and products sales volume and revenue. We expect limited printer sales to this key customer in the dental industry for the remainder of 2024, as this customer significantly expanded its printer capacity between 2022 and the quarter ended June 30, 2023. Partially offsetting the impact of the decline in printer sales to this key customer in the dental industry was an increase in the volume of materials sold to this customer, which also represents the largest contributor to the increase in revenue attributable to higher materials sales volume during the three months ended June 30, 2024. Sales of materials to this key customer returned to normalized levels; whereas, we experienced lower material sales to this key customer during the three months ended June 30, 2023 due to the customer's higher inventory on hand during the prior year period.

In addition, the $13.4 million decrease in printer and products revenue due to lower sales volume includes a $2.1 million decrease in revenue attributable to our regenerative medicine collaborative arrangement with a key strategic partner. Lower revenue attributable to this program is due to the loss of funding for kidney and liver R&D efforts under the collaborative arrangement with this key strategic partner, as well as a decrease in funded lung R&D activity performed under the collaborative arrangement during the three months ended June 30, 2024. Refer to the discussion of "Investing in Regenerative Medicine", within the "Recent Developments and Updates Regarding Strategic Initiatives" section of this MD&A, for details regarding the changes to this regenerative medicine program during the current fiscal year.

For the three months ended June 30, 2024, the $4.0 million unfavorable impact of price/mix on the products revenue reported by our Healthcare Solutions segment was primarily due to (1) the increase in materials sold to our key customer in the dental industry, both relative to the three months ended June 30, 2023 and as a percentage of the total materials sales, and (2) the lower pricing of the materials sales to this key dental industry customer for the three months ended June 30, 2024, as compared to the three months ended June 30, 2023. During the quarter ended June 30, 2024, the Company executed a new materials sales contract with this key dental industry customer, under which material sales to this key dental industry customer are expected to continue to exceed prior year levels for the remainder of the current year, but the pricing of the materials sold to this key dental customer is expected to remain lower than prior year's pricing for the remainder of the current year, including due to volume pricing discounts. Accordingly, price/mix is expected to continue to have an unfavorable impact on our Health Solutions materials and total revenue for the remainder of the current year.

The $0.8 million increase in Healthcare Solutions services revenue primarily relates to higher revenue attributable to personalized healthcare services, higher maintenance revenue related to the installed printer base at our key dental industry customer, and higher regenerative medicine milestone-based revenue during the period. Collectively, these increases in services revenue exceeded the decrease in parts manufacturing revenue for the three months ended June 30, 2024, as compared to the three months ended June 30, 2023.

#### Adjusted EBITDA

For the three months ended June 30, 2024, Adjusted EBITDA for our Healthcare Solutions segment decreased $2.6 million, or 23.0%, as compared to the three months ended June 30, 2023. The most significant contributor to this decrease in Adjusted EBITDA was the 19.7% decrease in segment revenue. For the three months ended June 30, 2024, the Healthcare Solutions segment realized (1) an increase in gross profit margin due to the change in the revenue mix between lower margin printers and products and higher margin materials and services revenue and (2) SG&A cost savings as a result of the Company's ongoing restructuring plan that commenced during fiscal year 2023. However, the higher gross profit margin realized on segment revenue and SG&A cost savings did not offset the overall decrease in segment revenue and higher segment R&D costs attributable to our various pre-commercial regenerative medicine activities.

### Industrial Solutions

#### Revenue

For the three months ended June 30, 2024, Industrial Solutions revenue decreased $3.0 million, or 4.4%, as compared to the three months ended June 30, 2023. This decrease in segment revenue was driven by a $4.7 million decrease in products revenue, partially offset by a $1.7 million increase in services revenue.

For the three months ended June 30, 2024, the $4.7 million decrease in Industrial Solutions products revenue was primarily due to a $4.8 million decrease in revenue attributable to lower sales volume, as a $0.7 million favorable impact of price/mix was substantially offset by a $0.6 million unfavorable impact of changes in foreign exchange rates. A $4.2 million decrease in materials revenue, primarily driven by lower sales volume, was the primary factor resulting in the $4.7 million decrease in products revenue. This decrease in the volume of materials sales was primarily driven by slower sell through at certain customers.

The $1.7 million increase in Industrial Solutions services revenue primarily relates to increased parts manufacturing revenue, as well as revenue generated from a significant contract that had not been executed as of June 30, 2023.

#### Adjusted EBITDA

For the three months ended June 30, 2024, Adjusted EBITDA for our Industrial Solutions segment increased $1.1 million, or 48.3%, as compared to the three months ended June 30, 2023. This increase in Adjusted EBITDA, notwithstanding the 4.4% decrease in segment revenue is primarily due to SG&A and R&D cost savings attributable to the Company's 2023 Restructuring Plan, which exceeded the decrease in segment gross profit due to lower reported revenue.

### Segment Financial Results for the Six Months Ended June 30, 2024 and 2023

*(in thousands)*

|  | Segment Revenue Six Months Ended June 30, 2024 | June 30, 2023 | Change | Segment Adjusted EBITDA Six Months Ended June 30, 2024 | June 30, 2023 | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Healthcare Solutions | $94,313 | $109,599 | $(15,286) | $12,492 | $16,459 | $(3,967) |
| Industrial Solutions | 121,844 | 139,831 | (17,987) | 5,440 | 9,166 | (3,726) |
| Total Segment Results | $216,157 | $249,430 | $(33,273) | $17,932 | $25,625 | $(7,693) |

### Healthcare Solutions

#### Revenue

For the six months ended June 30, 2024, Healthcare Solutions revenue decreased $15.3 million, or 13.9%, as compared to the six months ended June 30, 2023. This decrease in segment revenue was driven by a $16.7 million decrease in products revenue, consisting of revenue from printers, products and materials sales, partially offset by a $1.4 million increase in services revenue.

For the six months ended June 30, 2024, the $16.7 million decrease in Healthcare Solutions products revenue was primarily driven by an $8.6 million decrease in revenue attributable to lower sales volume and an $8.0 million decrease in revenue attributable the unfavorable impact of price/mix. The $8.6 million decrease in revenue attributable to lower sales volume reflects a $28.6 million decrease in printer and products revenue due to lower sales volume, which was only partially offset by a $20.0 million increase in materials revenue due to higher sales volume. For the six months ended June 30, 2024, a significant decline in printer sales to our key customer in the dental industry was the largest contributor to the lower printer and products sales volume and revenue. We expect limited printer sales to this key customer in the dental industry for the remainder of 2024, as this customer significantly expanded its printer capacity between 2022 and the quarter ended June 30, 2023. Partially offsetting the impact of the decline in printer sales to this key customer in the dental industry was an increase in the volume of materials sold to this customer, which also represents largest contributor to the increase in revenue attributable to higher materials sales volume during the six months ended June 30, 2024. Sales of materials to this key customer returned to normalized levels; whereas, we experienced significantly lower material sales volume to this key customer during the six months ended June 30, 2024 due to the customer's higher inventory on hand during the prior year period.

In addition, the $28.6 million decrease in printer and products revenue due to lower sales volume includes a $4.9 million decrease in revenue attributable to our regenerative medicine collaborative arrangement with a key strategic partner. Lower revenue attributable to this program is due to the loss of funding for kidney and liver R&D efforts under the collaborative arrangement with this key strategic partner, as well as a decrease in funded lung R&D activity performed under the collaborative arrangement during the six months ended June 30, 2024. Refer to the discussion of "Investing in Regenerative Medicine", within the "Recent Developments and Updates Regarding Strategic Initiatives" section of this MD&A, for details regarding the changes to this regenerative medicine program during the current fiscal year.

For the six months ended June 30, 2024, the $8.0 million unfavorable impact of price/mix on products revenue reported by our Healthcare Solutions segment was primarily due to (1) the increased sales of materials to our key customer in the dental industry, both relative to the six months ended June 30, 2023 and as a percentage of the total materials sales, and (2) the lower pricing of the materials sales to this key dental industry customer for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023. During the quarter ended June 30, 2024, the Company executed a new materials sales contract with this key dental industry customer, under which material sales to this key dental industry customer are expected to continue to exceed prior year levels for the remainder of the current year, but the pricing of the materials sold to this key dental customer is expected to remain lower than prior year's pricing for the remainder of the current year, including due to volume pricing discounts. Accordingly, price/mix is expected to continue to have an unfavorable impact on our Health Solutions materials and total revenue for the remainder of the current year.

The $1.4 million increase in Healthcare Solutions services revenue primarily relates to higher revenue attributable to personalized healthcare services, higher maintenance revenue related to the installed printer base at our key dental industry customer, and higher regenerative medicine milestone-based revenue during the period. Collectively, these increases in services revenue exceeded the decrease in parts manufacturing revenue for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023.

#### Adjusted EBITDA

For the six months ended June 30, 2024, Adjusted EBITDA for our Healthcare Solutions segment decreased $4.0 million, or 24.1%, as compared to the six months ended June 30, 2023. A significant contributor to this decrease in Adjusted EBITDA was the 13.9% decrease in segment revenue. For the six months ended June 30, 2024, the Healthcare Solutions segment realized both (1) an increase in gross profit margin due to the change in the revenue mix between lower margin printers and products and higher margin materials and services revenue and (2) SG&A cost savings as a result of the Company's ongoing restructuring plan activities that commenced during fiscal year 2023. However, the higher gross profit margin realized on segment revenue and SG&A cost savings did not offset the overall decrease in segment revenue and higher segment R&D costs attributable to our various pre-commercial regenerative medicine activities.

### Industrial Solutions

#### Revenue

For the six months ended June 30, 2024, Industrial Solutions revenue decreased $18.0 million, or 12.9%, as compared to the six months ended June 30, 2023. This decrease in segment revenue was driven by a $21.1 million decrease in products revenue, consisting of revenue from printers, products and materials sales, partially offset by a $3.1 million increase in services revenue.

For the three months ended June 30, 2024, the $21.1 million decrease in Industrial Solutions products revenue was primarily due to lower sales volumes for both printers and materials. Lower printer sales volume and revenue for the six months ended June 30, 2024 is due to a concentration of significant printer sales arrangements occurring during the first quarter of prior year; whereas, the Company did not benefit from similar arrangements during the first quarter of the current year period. Revenue from printer sales during the second quarter of the current year and the second quarter of the prior year was relatively flat. Materials sales revenue for the six months ended June 30, 2024 decreased $11.7 million, as compared to the six months ended June 30, 2024, primarily driven by slower sell through at certain customers.

The $3.1 million increase in Industrial Solutions services revenue primarily relates to increased parts manufacturing revenue, as well as revenue generated from a significant contract that had not been executed as of June 30, 2023.

#### Adjusted EBITDA

For the six months ended June 30, 2024, Adjusted EBITDA for our Industrial Solutions segment decreased $3.7 million, or 40.7%, as compared to the three months ended June 30, 2023. This decrease in Adjusted EBITDA is primarily attributable to the substantial decrease in segment gross profit attributable to the 12.9% decrease in segment revenue for the six months ended June 30, 2024, which was only partially offset by lower SG&A and R&D costs attributable to the execution of the Company's 2023 Restructuring Plan.

### Liquidity and Capital Resources

The following table sets forth the Company's operating working capital at June 30, 2024 and December 31, 2023.

*(Dollars in thousands)*

|  | June 30, 2024 | December 31, 2023 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Cash and cash equivalents | $192,732 | $331,525 | $(138,793) | (41.9)% |
| Accounts receivable, net | 97,447 | 101,497 | (4,050) | (4.0)% |
| Inventories | 141,743 | 152,188 | (10,445) | (6.9)% |
|  | 431,922 | 585,210 | (153,288) | (26.2)% |
| Less: |  |  |  |  |
| Current lease liabilities | 9,481 | 9,924 | (443) | (4.5)% |
| Accounts payable | 41,272 | 49,757 | (8,485) | (17.1)% |
| Accrued and other liabilities | 45,282 | 49,460 | (4,178) | (8.4)% |
|  | 96,035 | 109,141 | (13,106) | (12.0)% |
| Operating working capital | $335,887 | $476,069 | $(140,182) | (29.4)% |

We assess our liquidity in terms of our ability to generate cash to fund our operating, investing and financing activities. In doing so, we review and analyze our current cash on hand, the number of days our sales are outstanding, inventory turns, capital expenditure commitments and accounts payable turns. Our cash requirements, excluding acquisitions, primarily consist of funding working capital and capital expenditures. Differences between the amounts of working capital item changes in the cash flow statement and the balance sheet changes for the corresponding items are primarily the result of foreign currency translation adjustments, acquisitions and divestitures.

At June 30, 2024, cash and cash equivalents totaled $192.7 million and decreased $138.8 million since December 31, 2023. This decrease resulted primarily from cash used in operations of $36.3 million, capital expenditures of $7.2 million, and repayment on borrowings of $87.2 million.

Cash held outside the U.S. at June 30, 2024 was $59.9 million, or 31.1% of total cash and cash equivalents, compared to $65.8 million, or 19.8% of total cash and cash equivalents, at December 31, 2023. As our previously unremitted earnings have been subjected to U.S. federal income tax, we expect any repatriation of these earnings to the U.S. (e.g., via dividends) would not incur significant federal and state taxes. However, these dividends would be subject to foreign withholding taxes that are estimated to result in the Company incurring tax costs in excess of the cost to obtain cash through other means. Cash equivalents are comprised of funds held in money market instruments and are reported at their current carrying value, which approximates fair value due to the short-term nature of these instruments. We strive to minimize our credit risk by investing primarily in investment grade, liquid instruments and limit exposure to any one issuer depending upon credit quality. See “Cash Flow” discussion below.

### Cash Flow

The Company currently funds its operations, including working capital and capital expenditures, and acquisitions through cash on hand, cash equivalents, and financing activities as necessary. We expect that cash, cash equivalents, and other sources of liquidity, such as issuing equity or debt securities, subject to market conditions, will be available and sufficient to meet our anticipated cash requirements. The following is a summary of the changes in the Company’s cash flows followed by a brief discussion of these changes:

*(in thousands)*

|  | Six Months Ended June 30, 2024 | June 30, 2023 | Dollar Change |
| --- | ---: | ---: | ---: |
| Cash flow used in operating activities | $(36,308) | $(46,269) | $9,961 |
| Cash flow (used in) provided by investing activities | (9,505) | 150,587 | (160,092) |
| Cash flow used in financing activities | (90,380) | (4,926) | (85,454) |

### Cash flow from operations

For the six months ended June 30, 2024, cash used in operating activities was $36.3 million, and cash used in operating activities for the six months ended June 30, 2023 was $46.3 million. The $10.0 million reduction in cash used in operating activities is reflective of a $20.7 million favorable impact of changes in working capital accounts, partially offset by a $10.7 million increase in our net loss for the six months ended June 30, 2024, as compared to June 30, 2023, when adjusted for the $21.5 million gain on the extinguishment of debt recognized during the six months ended June 30, 2024 and the following additional non-cash items recognized in each reporting period: depreciation, amortization, and accretion expense; stock-based compensation expense; non-cash operating lease expense; inventory obsolescence, and other non-cash losses and provisions. The $20.7 million favorable working capital impact was primarily the result of increased inventory buildup during the six months ended June 30, 2023 in anticipation of forecasted sales.

### Cash flow from investing activities

For the six months ended June 30, 2024, cash used in investing activities was $9.5 million, which was primarily due to capital expenditures of $7.2 million and an incremental investment in NAMI of $2.5 million.

For the six months ended June 30, 2023, cash provided by investing activities was $150.6 million, which included $179.8 million of proceeds from the sales and maturities of short-term investments, partially offset by capital expenditures of $13.5 million and cash used for investments in strategically-aligned businesses totaling $15.7 million.

### Cash flow from financing activities

For the six months ended June 30, 2024, the cash flow used in financing activities was $90.4 million primarily due to repayment of borrowings of $87.2 million and taxes paid related to the net-share settlement of equity awards of $2.5 million.

For the six months ended June 30, 2023, the cash flow used in financing activities was $4.9 million primarily due to taxes paid related to the net-share settlement of equity awards of $4.6 million.

### Material Cash Requirements

The Company's material cash requirements consist of the following contractual and other obligations:

#### Indebtedness

At June 30, 2024, we had $214,378 of outstanding 0% convertible notes which mature in November of 2026 (the "Notes"). Management may consider pursuing additional long-term financing if it is appropriate in light of cash requirements for operations or strategic opportunities, which could result in higher financing costs.

#### Purchase Commitments

We have purchase commitments under legally enforceable agreements for goods and services with defined terms as to quantity, price and timing of delivery. The Company has certain purchase commitments under agreements with remaining terms in excess of a year, which primarily relate to printer assemblies, inventory, capital expenditures, and software licenses. As of June 30, 2024, such purchase commitments totaled $19.7 million, with approximately $10.9 million, expected to be due within the next twelve months.

#### Leases

The Company had operating and financing lease obligations (inclusive of interest) of $99.7 million at June 30, 2024, primarily related to real estate and equipment leases, of which approximately $8.1 million in payments are expected over the remainder of 2024.

#### National Additive Manufacturing Innovation ("NAMI") Joint Venture

In March 2022, Dussur and 3D Systems signed an agreement to form a joint venture intended to expand the use of additive manufacturing within the Kingdom of Saudi Arabia and surrounding geographies, including the Middle East and North Africa. The joint venture is to enable the development of Saudi Arabia's domestic additive manufacturing production capabilities, consistent with the Kingdom’s ‘Vision 2030,’ which is focused on diversification of the economy and long-term sustainability. In February 2023, the Company became a shareholder in the joint venture and now owns 49% of its common stock. 3D Systems was committed to an initial investment of approximately $6.5 million of cash into the joint venture, all of which has been funded as of June 30, 2024. In May 2024, the Company made another investment in NAMI, as further discussed in Note 6 to the condensed consolidated financial statements included in Item 1 of this Form 10-Q. Additional future investments in the joint venture are contingent upon agreement by the parties to the joint venture to invest additional capital. The future impact that participation in the joint venture will have on the Company’s financial position and cash flows is not expected to be material other than any potential cash outflow(s) that may be required to fund contingent investments.

#### Sources of Funding to Satisfy Material Cash Requirements

The Company believes that it has the financial resources needed to meet its anticipated cash requirements during the next twelve months. Cash requirements for periods beyond the next twelve months will depend on, among other things, the Company’s profitability and its ability to manage working capital requirements.

### Other Contractual Commitments

#### Indemnification

In the normal course of business we periodically enter into agreements to indemnify customers or suppliers against claims of intellectual property infringement made by third parties arising from the use of our products. Historically, costs related to these indemnification provisions have not been significant. We are unable to estimate the maximum potential impact of these indemnification provisions on our future results of operations.

To the extent permitted under Delaware law, we indemnify our directors and officers for certain events or occurrences, when the director or officer is, or was, serving at our request in such capacity, subject to limited exceptions. The maximum potential amount of future payments we could be required to make under these indemnification obligations is unlimited; however, we have directors’ and officers’ insurance coverage that may enable us to recover future amounts paid, subject to a deductible and to the policy limits. There is no assurance that the policy limits will be sufficient to cover all damages, if any.

### Critical Accounting Estimates

Our condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, costs and expenses, and related disclosures. On an ongoing basis, we evaluate our estimates and assumptions. Our actual results may differ from these estimates under different assumptions or conditions.

The following discussion summarizes changes in our critical accounting estimates that have occurred since December 31, 2023 and have had a material impact on our reported results.

See Note 2 to the consolidated financial statements in our 2023 Form 10-K for a summary of our significant accounting policies.

### New Critical Accounting Estimate

#### Systemic Bio Phantom Plan

During the year ended December 31, 2023, we began granting phantom unit awards ("Phantom Units") under a new compensation plan designed for employees and non-employees performing services for Systemic Bio, a wholly-owned subsidiary of 3D Systems. All awards granted under the plan are subsidiary-level awards. The Phantom Units granted under the plan include both a time-based vesting condition (generally 4 years, subject to acceleration in connection with specified liquidity events) and a market condition that is met if (1) the value of Systemic Bio exceeds a specified multiple of the capital invested in this subsidiary (the "hurdle") and (2) the business achieves a specified minimum internal rate of return. The market condition will be assessed upon (A) a trigger event (e.g., change-in-control, IPO, or plan expiration of December 31, 2030) and/or (B) an interim liquidity event (defined as January 1, 2028) that occurs prior to a trigger event. All awards granted under the plan are liability-classified due to our intention to settle these awards with cash; although, we have discretion to partially or fully settle these awards in equity upon vesting. Liability classification of the awards requires them to be remeasured at their estimated fair value at the end of each reporting period. Due to the presence of the market-condition and the fact that Systemic Bio does not have a readily available share price, the awards are valued using a Monte Carlo simulation with the assistance of a third-party valuation firm. This valuation requires significant judgment regarding the input of various assumptions and estimates, which include the projected cash flows of (including projected capital invested in) Systemic Bio, the probability and/or timing of a trigger event or a liquidity event, the expected stock price volatility for selected public companies with comparable characteristics to Systemic Bio, the discount for the lack of marketability of Systemic Bio as a privately-held company, and the risk-free interest rate. A change in management’s judgment regarding these assumptions or estimates can materially impact the periodic measurement of the liability and the related amount of compensation expense recognized in the Company’s consolidated financial statements.

The third-party valuation as of June 30, 2024 resulted in an increase in the estimated fair value of the Phantom Units and a corresponding $1.9 million increase in the expense recognized during the three and six months ended June 30, 2024, primarily as a result of a change in management's judgment regarding the estimated probability and timing for the occurrence of a trigger event. This change in estimate reduced basic and diluted earnings per share by $0.01 for the three and six months ended June 30, 2024. As of June 30, 2024, the Company has recognized a total of $2.6 million of expense for the Phantom Units granted since the inception of the underlying plan.

### Forward-Looking Statements

Certain statements made in this Form 10-Q that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from historical results or from any future results expressed, or implied by, such forward-looking statements. In many cases, you can identify forward-looking statements by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates,” or “plans” or the negative of these terms or other comparable terminology.

Forward-looking statements are based upon management’s beliefs, assumptions and current expectations concerning future events and trends, using information currently available, and are necessarily subject to uncertainties, many of which are outside our control. Although we believe that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at or by which any such performance or results will be achieved. A number of important factors could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements. These factors include without limitation:

- impact on our business as a result of macroeconomic events, including the Russia-Ukraine war and other geopolitical risks, recession, supply chain disruptions, inflation, interest rates and foreign exchange volatility;
- our ability to deliver products that meet changing technology and customer needs;
- our ability to identify strategic acquisitions, to integrate such acquisitions into our business without disruption and to realize the anticipated benefits of such acquisitions;
- our ability to realize anticipated benefits for future dispositions;
- impact of future write-off or write-downs of goodwill and intangible assets;
- the concentration of revenue and credit risk exposure from our largest customer;
- our ability to acquire and enforce intellectual property rights and defend such rights against third-party claims;
- our ability to protect our intellectual property rights and confidential information, including our digital content, from third-party infringers or unauthorized copying, use or disclosure;
- failure of our information technology infrastructure or inability to protect against cyber-attack;
- our ability to predict quarterly sales and manage product inventory due to uneven sales cycle;
- our ability to generate net cash flow from operations;
- our ability to service our debt and ability to raise funds necessary to settle conversions of the Notes in cash, repay the Notes at maturity, or repurchase the Notes in the case of a fundamental change;
- our ability to remediate material weaknesses in our internal controls over financial reporting and maintain effective internal controls;
- fluctuations in our gross profit margins, operating income or loss and/or net income or loss;
- our ability to efficiently conduct business outside the U.S.;
- our dependence on our supply chain for components and sub-assemblies used in our 3D printers and other products and for raw materials used in our print materials;
- our ability to manage the costs and effects of litigation, investigations or similar matters involving us or our subsidiaries;
- product quality problems that result in decreased sales and operating margin, product returns, product liability, warranty or other claims;
- our ability to retain our key employees and to attract and retain new qualified employees, while controlling our labor costs;
- our ability to successfully develop and commercialize regenerative medicine products ourselves, or in conjunction with development partners;
- disruption in our management information systems for inventory management, distribution, and other key functions;
- compliance with U.S. and other anti-corruption laws, data privacy laws, trade controls, economic sanctions, and similar laws and regulations;
- our ability to maintain our status as a responsible contractor under federal rules and regulations;
- changes in, or interpretation of, tax rules and regulations; and
- the other factors discussed in the reports we file with or furnish to the SEC from time to time, including the risks and important factors set forth in additional detail in Item 1A. “Risk Factors” in the 2023 Form 10-K.

Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements included herein are made only as of the date of this Form 10-Q and we undertake no obligation to publicly update or revise any forward-looking statement made by us or on our behalf, whether as a result of new information, future developments, subsequent events or circumstances or otherwise, except as required by law. All subsequent written or oral forward-looking statements attributable to us or individuals acting on our behalf are expressly qualified in their entirety by the cautionary statements referenced above.

## Market risk

As filed, 338 characters.

For a discussion of market risks at December 31, 2023, refer to Item 7A. “Quantitative and Qualitative Disclosures about Market Risk” in our 2023 Form 10-K. During the three months ended June 30, 2024, there were no material changes or developments that would materially alter the market risk assessment performed as of December 31, 2023.

## Controls and procedures

As filed, 1,193 characters.

### Evaluation of Disclosure Controls and Procedures

As of June 30, 2024, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) pursuant to Rules 13a-15 and 15d-15 under the Exchange Act. Based on this evaluation, management has concluded that our disclosure controls and procedures were not effective as of June 30, 2024 due to the material weaknesses discussed in our 2023 Form 10-K.

### Changes in Internal Control Over Financial Reporting

We are in the process of implementing certain changes to our internal controls to remediate the material weaknesses described in our 2023 Form 10-K. Except as noted above, there were no changes in the Company’s internal control over financial reporting during the three months ended June 30, 2024 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

## Risk factors

As filed, 8,834 characters.

In addition to the risk factors set forth below and the other information set forth in this Form 10-Q, you should carefully consider the factors discussed under Part I, Item 1A, “Risk Factors” in our 2023 Form 10-K. These factors could materially adversely affect our business, financial condition, liquidity, results of operations and capital position, and could cause our actual results to differ materially from our historical results or the results contemplated by the forward-looking statements contained in this Form 10-Q. Except as disclosed below, there have been no material changes to the risk factors described in Part I, Item 1A, “Risk Factors,” included in our 2023 Form 10-K.

**We may not have sufficient cash or the ability to raise the funds necessary to settle conversions of the 0% Convertible Senior Notes due 2026 (the "Notes") in cash, repay the Notes at maturity, or repurchase the Notes as required following a fundamental change.**

As of June 30, 2024, we had approximately $214.4 million of outstanding Notes. Our ability to service and/or refinance the Notes, or make cash payments in connection with any conversions of the Notes, depends on our future performance, which is subject to economic, financial, competitive, and other factors beyond our control. Our business may not generate cash flow from operations in the future sufficient to service the Notes. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, including selling assets, refinancing the Notes, or obtaining additional debt financing or equity capital on terms that may be onerous or highly dilutive. Our ability to refinance the Notes will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations. In addition, any of our future debt agreements may contain restrictive covenants that may prohibit us from adopting any of these alternatives.

The Company’s failure to file the 2023 Form 10-K and provide it to the Trustee by April 1, 2024 represented a default under the terms of the indenture governing the Notes (the "Indenture"). In addition, the Company’s failure to file our Form 10-Q for the three months ended March 31, 2024 and provide it to the Trustee within 15 days of the filing deadline (after giving effect to any grace period provided by Rule 12b-25 under the Exchange Act) represented an incremental default under the terms of the Indenture. The Company filed its 2023 Form 10-K and provided a copy of this filing to the Trustee on August 13, 2024, curing the first default referenced above. The Company filed its Form 10-Q for the three months ended March 31, 2024 and provided a copy of this filing to the Trustee on August 20, 2024, curing the incremental default referenced above. Although the Company cured these defaults and did not incur any special interest as a result of these defaults, our failure to comply with these or other covenants of the Indenture in the future could result in an event of default which, if not cured or waived, could result in the acceleration of our debt or cause us to incur special interest payments. For further information regarding the non-compliance with the terms of the Indenture, refer to Note 9 to the Financial Statements.

In the event the conditional conversion feature of the Notes is triggered, holders of Notes will be entitled to convert the Notes at any time during specified periods at their option. If one or more holders elect to convert their Notes, we would be required to settle any converted principal through the payment of cash, which could adversely affect our liquidity. In addition, even if holders do not elect to convert their Notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the Notes as a current rather than long-term liability, which would result in a material reduction of our net working capital.

In addition, holders of the Notes have the right to require us to repurchase all or a portion of their Notes upon the occurrence of a Fundamental Change (as defined in the Indenture) at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased. If the Notes have not previously been converted or repurchased, we will be required to repay such Notes in cash at maturity.

Our ability to make required cash payments in connection with conversions of the Notes, repurchase the Notes in the event of a Fundamental Change, or to repay or refinance the Notes at maturity will depend on market conditions and our future performance, which is subject to economic, financial, competitive, and other factors beyond our control. As a result, we may not have enough available cash or be able to obtain financing at the time we are required to repurchase or repay the Notes or pay cash with respect to Notes being converted.

**As a result of the delayed filing of our 2023 Form 10-K, our Form 10-Q for the quarter ended March 31, 2024, and this Form 10-Q, the Company has experienced risks and costs and expects to experience additional risks and costs in the future, including with respect to the SEC's ongoing investigation.**

As a result of the circumstances giving rise to the delayed filing of our 2023 Form 10-K, our Form 10-Q for the quarter ended March 31, 2024, and this Form 10-Q, the Company experienced risks and costs and expects to experience additional risks and costs in the future. The audit of the financial statements included in our 2023 Form 10-K was time-consuming, required the Company to incur additional incremental expenses and affected management’s attention and resources. Further, the measures to strengthen internal controls being implemented continued to require and will likely require in the future greater management time and Company resources to implement and monitor. Although we have now filed our 2023 Form 10-K, our Form 10-Q for the quarter ended March 31, 2024, and this Form 10-Q, our failure to make these filings in a timely manner has led to further investigation and scrutiny by the SEC, which has been conducting a formal investigation of the Company since April 2022 as a follow on to the previously disclosed SEC voluntary request for documents. Although the Company is currently cooperating with the SEC, the Company cannot predict the ultimate outcome of the SEC’s investigation. Any allegations or adverse findings by the SEC could harm our reputation, negatively impact our stock price and have a material adverse effect on our business, financial condition and results of operations. Moreover, the expense and distraction to management of cooperating with and responding to the SEC could have a material adverse effect on the Company even if the investigation is ultimately closed or resolved in a manner favorable to the Company. See also the risk factor below entitled “We are no longer eligible to use a Form S-3 registration statement, which could impair our capital-raising activities.”

**We are no longer eligible to use a Form S-3 registration statement, which could impair our capital-raising activities.**

As a result of our failure to timely file our 2023 Form 10-K, our Form 10-Q for the quarter ended March 31, 2024, and this Form 10-Q with the SEC, we are no longer eligible to use a Form S-3 registration statement. Further, as a result of the late 2023 Form 10-K filing, the late Form 10-Q filing for the quarter ended March 31, 2024 and this late Form 10-Q filing, we are also no longer a “well-known seasoned issuer,” as such term is used in the SEC’s regulations, which otherwise would allow us to, among other things, file automatically effective Form S-3 registration statements. Our eligibility to use a Form S-3 registration statement may not be restored until September 1, 2025, and then only if we have not had any other filing delinquency that would preclude Form S-3 eligibility and satisfy all other requirements for Form S-3 eligibility. During any period when we are not eligible to use Form S-3 or qualify as a “well known seasoned issuer,” our capital-raising ability may be impaired. Under these circumstances, we would be required to conduct the offering on an exempt basis, such as in accordance with Rule 144A, or file a registration statement on Form S-1. Using a Form S-1 registration statement for a public offering would likely take significantly longer than using a registration statement on Form S-3 and increase our transaction costs, and could, to the extent we are not able to conduct offerings using alternative methods, adversely impact our ability to raise capital or complete acquisitions of other companies in a timely manner.

Filed Aug 29, 2024.
Source: SEC EDGAR, the filing index for accession 0000910638-24-000041. Last ingested by Listed: Nov 15, 2026, 00:01 ET. No prices; not investment advice.
